Brevan Howard Capital Management’s Definium Therapeutics DFTX Stock Holding History

Brevan Howard Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.38M	Sell	156,812 -54,676	-26%	-$1.35M	0.05%	243
2026 Q1	$4M	Buy	211,488 +200,374	+1,803%	+$3.4M	0.04%	320
2025 Q4	$149K	Buy	+11,114	New	+$138K	﹤0.01%	1633
2024 Q2	–	Sell	-10,649	Closed	-$100K	–	1272
2024 Q1	$100K	Buy	+10,649	New	+$60.7K	﹤0.01%	894

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Brevan Howard Capital Management's DFTX Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Definium Therapeutics (DFTX) stake by 26% in Q2 2026, selling an estimated $1.35M and leaving 156,812 shares worth $7.38M. The position accounts for 0.05% of the portfolio, ranked #243.

Brevan Howard Capital Management first reported a position in DFTX in Q1 2024 and has held it in 4 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Brevan Howard Capital Management held 156,812 shares of Definium Therapeutics worth $7.38M as of Q2 2026.
Brevan Howard Capital Management sold 54,676 Definium Therapeutics shares in Q2 2026, an estimated $1.35M.
Definium Therapeutics made up 0.05% of Brevan Howard Capital Management's portfolio in Q2 2026, its #243 holding.
Brevan Howard Capital Management first reported a position in Definium Therapeutics in Q1 2024 and has held it in 4 quarters since.
361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.